Remove 2004 Remove Leads Remove Pharma Remove Safety
article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

Oncoral (Ascelia Pharma) is a novel patented tablet formulation of irinotecan, currently in Phase II clinical development, for daily dosing at home. Secondary endpoints will include response rate, overall survival, pharmacokinetics, safety and tolerability. J Clin Oncol, 2004; 22(14): 2849-2855. About the author.

article thumbnail

The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next

PM360

At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. But now the big pharma companies have also jumped into the game.

article thumbnail

Delivering Improved Disease Awareness Through More Strategic Partnerships

PM360

Can more than 20 pharma companies unite around messaging for biomarker testing even though everyone seems to call it something different? Historically, pharma companies only do marketing for biomarker testing related to the type of drug they were launching,” says Nikki Martin, Senior Director, Precision Medicine Initiatives, LUNGevity. “As

Education 105